BioNTech SE

BioNTech SE is a global next-generation immunotherapy company focused on pioneering novel medicines against cancer, infectious diseases, and other serious diseases. Founded in 2008, BioNTech combines decades of immunology research with a multi-technology innovation engine spanning mRNA therapies, protein-based therapeutics including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). The company's first marketed pharmaceutical product is Comirnaty, the COVID-19 mRNA vaccine developed in collaboration with Pfizer, which has shipped over 5 billion doses globally. BioNTech's primary strategic focus is oncology, where it is advancing a diversified clinical pipeline across multiple cancer types including lung cancer, breast cancer, colorectal cancer, and endometrial cancer. Key pipeline assets include pumitamig (a bispecific PD-L1/VEGF-A immunomodulator with seven global registrational trials), trastuzumab pamirtecan (a HER2-targeting ADC with Breakthrough Therapy designation), elfetabart drozuntecan (a B7-H3 ADC), gotistobart (a selective Treg-depleting antibody), and autogene cevumeran (an individualized mRNA cancer immunotherapy). In infectious diseases, BioNTech is developing vaccines for influenza, herpes simplex virus, tuberculosis, mpox, malaria, and HIV. The company completed its acquisition of CureVac N.V. in early 2026, expanding its mRNA technology capabilities. BioNTech operates an integrated model encompassing GMP manufacturing, clinical development, commercial capabilities, and AI/machine learning-driven drug discovery, and is building out commercial infrastructure in the United States ahead of potential oncology product launches. The company is designated as an operator of critical infrastructure under German law, subjecting acquisitions by non-EU/non-EFTA investors of 10% or more voting rights to German federal government screening and approval. Updated Aug 4, 2026